HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luisetti, M. Articles by Stockley, R.A. Search for Related Content PubMed PubMed Citation Articles by Luisetti, M. Articles by Stockley, R.A.

₁-antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001

¹ Laboratory of Biochemistry and Genetics, Dept of Respiratory Diseases, IRCCS San Matteo, Pavia, Italy, ² Dept of Pneumology, Clinic and Provincial Hospital, Barcelona, Spain, ³ Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham, UK

CORRESPONDENCE: M. Luisetti, Laboratorio di Biochimica e Genetica, Clinica di Malattie dell'Apparato Respiratorio, IRCCS Policlinico San Matteo, Via Taramelli 5, 27100, Pavia, Italy. Fax: 39 0382502269. E-mail: m.luisetti@smatteo.pv.it

Keywords: ₁-antitrypsin deficiency, epidemiology, genetics, therapy

Received: December 12, 2001
Accepted April 12, 2002

Abstract

The Alpha One International Registry is a scientific foundation established to comply with a World Health Organization recommendation to develop a multinational registry of ₁-antitrypsin deficiency, with the aim of creating a common database of subjects recognised in a standardised way.

A commitment of the Alpha One International Registry members, belonging to 15 national registries, is to meet every 2 yrs in an open scientific conference to provide a scientific and clinical update on the deficiency. The second Alpha One International Registry meeting was held in Rapallo (Genoa, Italy) on September 27th–28th, 2001, and 26 speakers provided an exhaustive overview of all aspects of ₁-antitrypsin deficiency, including epidemiology, genetics, biochemistry, associated conditions, established and novel therapeutic options, and markers of efficacy. In the framework of a rare and often under-recognised condition, this meeting is likely to be central to improving understanding and increasing awareness of ₁-antitrypsin deficiency.

This article has been cited by other articles:

				G. Tirado-Conde, B. Lara, and M. Miravitlles Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency Therapeutic Advances in Respiratory Disease, February 1, 2008; 2(1): 13 - 21. [Abstract] [PDF]

				R. A. Stockley, M. Luisetti, M. Miravitlles, E. Piitulainen, P. Fernandez, and on behalf of the Alpha One International Registry Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development Eur. Respir. J., March 1, 2007; 29(3): 582 - 586. [Abstract] [Full Text] [PDF]

				I Ferrarotti, J Baccheschi, M Zorzetto, C Tinelli, L Corda, B Balbi, I Campo, E Pozzi, G Faa, P Coni, et al. Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency J. Med. Genet., March 1, 2005; 42(3): 282 - 287. [Full Text] [PDF]

				M Luisetti and N Seersholm {alpha}1-Antitrypsin deficiency {middle dot} 1: Epidemiology of {alpha}1-antitrypsin deficiency Thorax, February 1, 2004; 59(2): 164 - 169. [Abstract] [Full Text] [PDF]